NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis $47.25 -0.99 (-2.05%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$46.50▼$49.0050-Day Range$37.50▼$51.1752-Week Range$14.19▼$72.29Volume225,530 shsAverage Volume516,299 shsMarket Capitalization$2.76 billionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Apogee Therapeutics alerts: Email Address Apogee Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.1% Upside$78.50 Price TargetShort InterestBearish21.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 7 Articles This WeekInsider TradingSelling Shares$5.22 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.57) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 starsMedical Sector605th out of 910 stocksBiological Products, Except Diagnostic Industry95th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has received no research coverage in the past 90 days.Read more about Apogee Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.97% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 5.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APGE. Previous Next 2.3 News and Social Media Coverage News SentimentApogee Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Apogee Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,218,774.00 in company stock.Percentage Held by Insiders36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Apogee Therapeutics Stock (NASDAQ:APGE)Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Read More APGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APGE Stock News HeadlinesSeptember 7 at 9:06 AM | insidertrades.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 6,665 Shares of StockAugust 24, 2024 | insidertrades.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CFO Sells 6,000 Shares of StockSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 10, 2024 | insidertrades.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 7,335 Shares of StockSeptember 7 at 3:42 AM | finance.yahoo.comInsider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)August 28, 2024 | americanbankingnews.comHead to Head Review: Alector (NASDAQ:ALEC) & Apogee Therapeutics (NASDAQ:APGE)August 28, 2024 | americanbankingnews.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CFO Sells $289,560.00 in StockAugust 24, 2024 | finance.yahoo.comInsider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 19, 2024 | globenewswire.comApogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesAugust 17, 2024 | finance.yahoo.comAPGE Sep 2024 45.000 put (APGE240920P00045000)August 13, 2024 | finanznachrichten.deApogee Therapeutics, Inc.: Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | msn.comInflation, Retail Outlooks Lift Wall Street Pre-Bell; Asia, Europe SteadyAugust 12, 2024 | globenewswire.comApogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial ResultsAugust 10, 2024 | finance.yahoo.comInsider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)August 10, 2024 | finance.yahoo.comApogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 SharesJuly 19, 2024 | markets.businessinsider.comNewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsJune 18, 2024 | seekingalpha.comApogee Therapeutics: Infrequent Dosing Advantage In Biotech PlaySee More Headlines Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$43.00 Potential Upside/Downside+66.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.05% Return on Assets-19.33% Debt Debt-to-Equity RatioN/A Current Ratio27.70 Quick Ratio27.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.19 per share Price / Book2.75Miscellaneous Outstanding Shares58,456,000Free Float37,353,000Market Cap$2.76 billion OptionableOptionable Beta2.74 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Comp: $1.17MMs. Jane Pritchett V. Henderson (Age 58)Chief Financial Officer Comp: $843.64kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Comp: $870.83kMs. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 48)Chief Legal Officer & Corporate Secretary Ms. Emily CoxVP & Head of PeopleDr. Rebecca Dabora Ph.D. (Age 64)Chief Development Officer Ms. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 48)Senior Vice President of Finance More ExecutivesKey CompetitorsCatalentNYSE:CTLTQiagenNYSE:QGENLegend BiotechNASDAQ:LEGNSummit TherapeuticsNASDAQ:SMMTRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsMichael Thomas HendersonSold 40,000 sharesTotal: $1.90 M ($47.62/share)Carl DambkowskiSold 6,665 sharesTotal: $316,987.40 ($47.56/share)Jane HendersonSold 6,000 sharesTotal: $289,560.00 ($48.26/share)Point72 Asset Management L.P.Sold 217,968 shares on 8/19/2024Ownership: 0.461%Driehaus Capital Management LLCBought 54,107 shares on 8/16/2024Ownership: 3.623%View All Insider TransactionsView All Institutional Transactions APGE Stock Analysis - Frequently Asked Questions How have APGE shares performed this year? Apogee Therapeutics' stock was trading at $27.94 on January 1st, 2024. Since then, APGE shares have increased by 69.1% and is now trading at $47.25. View the best growth stocks for 2024 here. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Apogee Therapeutics' top institutional shareholders include Driehaus Capital Management LLC (3.62%), Perceptive Advisors LLC (3.60%), Affinity Asset Advisors LLC (1.43%) and First Turn Management LLC (0.54%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski and Jane Henderson. View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APGE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts